At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 101 enrolled
Drug / intervention
losartan potassiumdrug
Likely dose
losartan potassium 0.1 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III, Randomized, Open-Label, Parallel-Group, Dose-Ranging Clinical Trial to Study the Safety and Efficacy of MK954/Losartan Potassium in Pediatric Patients With Hypertension
In Brief
A Phase 3 clinical trial evaluating losartan potassium for Hypertension. Completed, enrolled 101 participants.
Detailed Summary
This study will explore the dose-response of losartan as well as the safety and tolerability in children from 6 months to 6 years of age.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 2008
Enrollment StartMar 2009
Primary CompletionAug 2012
TodayJul 2026
First PostedSep 22, 2008
Enrollment StartMar 1, 2009
Primary CompletionAug 14, 2012
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 17.8 years ago
Interventions
losartan potassiumdrug
losartan potassium, dry powder, to be suspended in liquid and given orally, once daily; doses will start at 0.1 mg/kg, 0.3 mg/kg, and 0.7 mg/kg, respectively, in the three study arms and can be escalated up to 1.4 mg/kg (maximum dose 100 mg) until target blood pressure is reached.